EUCTR2005-004989-17-FR进行中（未招募）1 期
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients that meet all of the following Inclusion Criteria may be enrolled into the study:
- •1) Age 18 years or older;
- •2) Moderate to severe CKD (sCr = 2.0 mg/dL[= 177 µmol/L] and = 5.0 mg/dL[= 442 µmol/L]), not anticipated to require dialysis or renal transplant within the next 6 months;
- •3) Patient survival expected to be no less than one year;
- •4) Serum creatinine = 2.0 mg/dL [= 177 µmol/L] and = 5.0 mg/dL [= 442 µmol/L] at the initial Screening visit;
- •5) Proteinuria / Progressive deterioration in renal function:
- •Urinary total protein to urinary total creatinine ratio (both values measured as mg/dL, or other like units) must be = 0.5 on a spot void obtained at the Screening visit
- •If the urinary total protein to urinary total creatinine ratio is <0.5, then the patient may return for a second Screening visit 3 months later. If the sCr value at the second Screening visit is >10% higher than the first Screening visit but not > 5.0 mg/dL [= 442 µmol/L] or if the urinary total protein to urinary total creatinine ratio is = 0.5, then the patient may be enrolled (See Appendix E in the Protocol for a listing of qualifying sCr values based on initial and second Screening visit values).
- •6) Sitting blood pressure = 160/90 mmHg at both Screening and Baseline visits. In addition, blood pressure, if measured, must have been stable in hypertensive patients over the 3 months prior to Screening, with no more than 1 blood pressure reading > 160/90 mmHg;
- •7) In patients being treated for hypertension, they should be on a stable anti-hypertensive regimen, defined as no changes in anti-hypertensive medications or doses in the last 3 months prior to the Baseline visit, and to include a stable dose of either an ACEI or ARB unless contraindicated;
- •8) Stable nutritional status; and
- •9) Willingness to comply with the study and sign a written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients that meet any of the following Exclusion Criteria must not be enrolled into the study:
- •1) Obstructive or reversible cause of kidney disease;
- •2) Nephrotic syndrome defined as a ratio of urinary total protein to urinary creatinine (both components measured as mg/dL or other like units) of > 6.0 as measured on a spot void;
- •3) Adult polycystic kidney disease;
- •4) History of previous kidney transplant;
- •5) History of alcohol or drug abuse within the past 12 months;
- •6) Known human immunodeficiency virus (HIV) infection;
- •7) Received immunosuppressive therapy (including systemic corticosteroids for more than 5 days at a daily dose in excess of 0.1 mg/kg, prednisone equivalent) in the past 3 months, or anticipated to require such treatment during the study course;
- •8) History of recent (within the past 6 months) accelerated or malignant hypertension;
- •9) Patients who are likely to require changes in ACEI or ARB regimens during the course of this study;
- •10) Uncontrolled arrhythmia or severe cardiac disease (New York Heart Association Class III -IV), including myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, cerebrovascular accident, or transient ischemic attack within the past 6 months;
- •11) History of malabsorption, inflammatory bowel disease, hiatal hernia, active peptic ulcer, or severe GI dysmotility, not attributable to the use of a phosphate binder;
- •12) History of cancer within the past 5 years (cervical carcinoma in situ, low-grade cutaneous malignancy, or other low grade malignancy are exemptions);
- •13) Alanine transaminase (ALT) or aspartate transaminase (AST) values > 2.5 times the upper limit of normal (ULN);
- •14) Received any investigational agent or participated in a clinical study within the previous 3 months;
- •15) Presence of any significant medical condition that might create an undue risk with study participation, or significantly confound the collection of safety and efficacy data in this study; or
- •16) For women of childbearing potential, a positive pregnancy test result of serum beta human chorionic gonadotropin (ßHCG) or unwillingness to use approved single barrier or oral contraception, or unwillingness to be sexually abstinent.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644